As a defective medication lawyer, I have closely watched the continuing reports of problems with drugs manufactured by McNeil Pharmaceuticals. In January, I wrote about the unsettling recall of products…
Read More
The U.S. Food and Drug Administration announced Aug. 24 that it is looking into safety problems with a popular weight-loss drug. According to the Los Angeles Times, the agency has…
Read More
Pharmaceutical company Pfizer Inc. will pay $2.3 billion to the federal and state governments over allegations that it illegally marketed several drugs for off-label uses, the New York Times reported…
Read More
The FDA plans to study how well consumers absorb information and respond to television advertisements for prescription drugs, American Medical News reported Feb. 2. The agency is interested in how…
Read More
One of the most difficult Effexor-related birth defects is the condition known as Persistent Pulmonary Hypertension of the Newborn (PPHN). Described briefly, PPHN results in the infant being unable to…
Read More
As a dangerous prescription drug attorney, part of my job revolves around the effectiveness of warning labels on pharmaceutical products. So I was interested to see a recent article about…
Read More
The FDA is requiring changes in label for gadolinium-based contrast agents (GBCAs) to minimize the risk of nephrogenic systemic fibrosis (NSF), a rare, but serious, condition associated with the use…
Read More
Expert testimony at trial is very important to my work as a defective drug attorney. Because individual jurors rarely have a background in the medical field, an expert is not…
Read More
A recent New York Times article about the drug company GlaxoSmithKline's agreement to pay a $750 million settlement to the FDA caught my eye, as a defective prescription drugs attorney.…
Read More
As a defective drug attorney, I’ve kept an eye on the problems plaguing St. Louis-area drug maker KV Pharmaceutical. The company’s Ethex subsidiary was permanently shut down in 2010 after…
Read More